|
Volumn 14, Issue 2, 2007, Pages 387-391
|
Broad-spectrum caspase inhibitors: From myth to reality? [5]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
2,6 DIFLUOROPHENOXYMETHYLKETONE DERIVATIVE;
3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID;
CASPASE;
CASPASE INHIBITOR;
CATHEPSIN;
CYSTEINE PROTEINASE INHIBITOR;
FLUOROMETHYLKETONE DERIVATIVE;
UNCLASSIFIED DRUG;
AMINO ACID SEQUENCE;
APOPTOSIS;
CATALYSIS;
CELL MEMBRANE PERMEABILITY;
CELL PROTECTION;
CLINICAL TRIAL;
CYTOTOXICITY;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG SAFETY;
ENZYME ACTIVE SITE;
ENZYME ACTIVITY;
ENZYME ASSAY;
ENZYME INACTIVATION;
ENZYME INHIBITION;
ENZYME STRUCTURE;
GENETIC CODE;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
LETTER;
NONHUMAN;
PHARMACOPHORE;
PRIORITY JOURNAL;
PROTEIN DEGRADATION;
SINGLE DRUG DOSE;
AMINO ACID CHLOROMETHYL KETONES;
ANIMALS;
BENZYL COMPOUNDS;
CASPASES;
CATHEPSINS;
ENZYME INHIBITORS;
HUMANS;
HYDROCARBONS, FLUORINATED;
MICE;
NEURONS;
QUINOLINES;
|
EID: 33846215056
PISSN: 13509047
EISSN: 14765403
Source Type: Journal
DOI: 10.1038/sj.cdd.4402044 Document Type: Letter |
Times cited : (118)
|
References (22)
|